Dopavision Announces Topline Results in Clinical Trial of Targeted Photobiomodulation Approach for Progressive Myopia

Safe and Tolerable: MyopiaX-1 proof-of-concept clinical trial (NCT04967287) supports MyopiaX's excellent safety and tolerability profile with no untoward safety events. Novel Approach: Dopavision's

Related Keywords

Germany ,German ,Novartis Pharma ,Dopavision Gmb ,Ian Flitcroft ,Mark Wuttke ,Ababax Health ,Boehringer Ingelheim Venture Fund ,German Federal Ministry Of Education ,Business Wire ,Coordinating Investigator ,With Myopiax ,Seventure Partners ,German Federal Ministry ,Executive Officer ,Ihr Portfolio ,